Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
The European Medicines Agency (EMA) has announced that it has started a rolling review of data on the use of the drug of the moment – Gilead Sciences’ remdesivir – for the treatment of coronavirus disease (COVID-19). 1 May 2020
Biotechnology
Former Celgene acute myeloid leukemia (AML) candidate CC-486 will be evaluated by the US regulator under its Priority Review scheme. 1 May 2020
Biotechnology
Shares in US biotech Seattle Genetics were 8% higher within minutes of trading starting on Friday, following the announcement of the company’s quarterly financial results. 1 May 2020
Biotechnology
US biotech giant Amgen late yesterday announced financial results for the first quarter of 2020, showing that revenues increased 11% to $6.2 billion versus the like quarter of 2019. 1 May 2020
Biotechnology
The first batches of Moderna Therapeutics’ COVID-19 vaccine could be rolling off newly-built production lines by July 2020. 1 May 2020
Biotechnology
Gilead Sciences has reported first quarter revenues of $5.5 billion, beating analysts’ expectations of around $5.45 billion, an increase of 5% compared with the same period in 2019. 1 May 2020
Biotechnology
The COVID-19 outbreak is having a terrible impact on patients and frontline medical professionals in many parts of the USA, but that is far from its only effect on the country’s healthcare system. 30 April 2020
Biotechnology
French biotech firm Valneva, a pure play vaccine developer, and US pharma giant Pfizer today announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase II clinical studies. 30 April 2020
Biotechnology
Vertex Pharmaceuticals’ Trikafta (elexacaftor/tezacaftor/ivacaftor) comes with evidence of providing a major net benefit for patients, but the price tag needs to be massively reduced to align with these benefits. 30 April 2020
Biotechnology
Shares of Pharming Group were up almost 4% at 1.32 euros in late afternoon trading today, as the Dutch biotech announced that the European Commission has approved an extension in the indication of Ruconest (conestat alfa). 30 April 2020
Biotechnology
UK biotechnology Stabilitech is developing next-generation vaccines and biopharmaceuticals, but is now seeking an investment of £6 million (~$7.5 million) to fund clinical trials and manufacturing of an oral coronavirus vaccine, OraPro-COVID-19, which, if approved, could be a self-administered capsule. 30 April 2020
Biotechnology
The US Food and Drug Administration has approved the supplemental New Drug Application (sNDA) for Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor. 30 April 2020
Biotechnology
There was a time when executives at Teva Pharmaceutical Industries thought that their product might be the third anti-calcitonin gene-related peptide (CGRP) drug to be recommended by the National Institute for Health and Care Excellence (NICE). 29 April 2020
Biotechnology
Shares in US biotech Gilead Sciences jumped by 6.7% in morning trading on Wednesday following updates on trials of the investigational antiviral drug remdesivir in severe COVID-19. 29 April 2020
Biotechnology
Swedish Orphan Biovitrum, the Nordic biotech company known as Sobi, today announced its results for the first quarter 2020 showing strong growth, but still seeing the company’s shares down nearly 3.5% at 185.60 Swedish kronor by close of trading. 29 April 2020
Biotechnology
Interleukin (IL)-17A blocker Cosentyx (secukinumab) has picked up a new approval in Europe, for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA). 29 April 2020
Biotechnology
UK-based Almac Discovery has announced a research tie-up with US pharma giant Merck & Co focusing on the generation of new small molecule inhibitors against specified deubiquitinase (DUB) targets for a range of neurodegenerative and other diseases. 29 April 2020
Biotechnology
A novel AXL kinase inhibitor from Norwegian biotech BerGenBio is to be fast-tracked through a new Phase II trial program led by the British government. 29 April 2020
Biotechnology
Blueprint Medicines’ shares dropped 19% in early trade on Tuesday and were still down 17.3% at $58.63 at close, after the rare diseases and cancer immunotherapy company announced that its late-stage trial of already marketed Ayvakit (avapritinib) in an extended indication was a flop. 29 April 2020
Biotechnology
US drug giant Merck & Co was trading 3% lower after two hours of trading on Tuesday. 28 April 2020
All news
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze